Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Sci Transl Med. Author manuscript; available in PMC 2013 April 17.
Published in final edited form as:
PMCID: PMC3628825

Overexpression of Methyl-CpG Binding Protein 2 Impairs TH1 Responses


The DNA binding protein methyl-CpG binding protein 2 (MeCP2) critically influences neuronal and brain function by modulating gene expression, and children with overexpression of the MECP2 gene exhibit postnatal neurological syndromes. We demonstrate that some children with MECP2 duplication also display variable immunological abnormalities that include reductions in memory T and B cells and natural killer cells and immunoglobulin assay responses. Moreover, whereas mice with MeCP2 overexpression were unable to control infection with the intra-macrophage parasite Leishmania major and secrete interferon-γ (IFN-γ) from involved lymph nodes, they were able to control airway fungal infection by Aspergillus niger and mount protective T helper cell type 2 (TH2)–dependent allergic responses. Relative to normal T cells, TH cells from children and mice with MECP2 duplication displayed similar impairments in IFN-γ secretion and TH1 responses that were due to both MeCP2-dependent suppression of IFN-γ transcription and sequestration of the IFN-γ locus as assessed by chromatin immunoprecipitation assay. Thus, overexpressed MeCP2 aberrantly suppresses IFN-γ secretion from TH cells, potentially leading to a partially immunodeficient state. Our findings establish a rational basis for identifying, treating, and preventing infectious complications potentially affecting children with MECP2 duplication.


Methyl-CpG binding protein 2 (MeCP2) is a pleiotropic DNA binding protein that preferentially binds to methylated CpGs and regulates gene expression (1). Duplication of the genomic region that contains the MECP2 gene (Xq28) is linked to a syndrome characterized by multiple respiratory infections, hypertelorism, severe central nervous system (CNS) deterioration, and early death (24). The common core phenotype of these affected boys includes infantile hypotonia, mild dysmorphic features, severe to profound intellectual disability, poor or absent speech development, epilepsy, and progressive spasticity (3). The smallest region of genomic overlap that is associated with this phenotype includes the MECP2 and interleukin-1 (IL-1) receptor–associated kinase 1 [IRAK1; Mendelian Inheritance in Man (MIM): 300283] genes (3, 5, 6). Mice subsequently engineered to overexpress human MECP2 develop a similarly progressive neurological disease (7). The similar phenotypes of mice expressing twice the normal levels of MeCP2 and humans with increasing MECP2 dosage from duplication to triplication (6, 8) indicate that MECP2 duplication causes the neurological disorder that is now termed MECP2 duplication syndrome (MIM: 300260).

Many children with MECP2 duplication and triplication syndromes also experience severe, often lethal, pneumonias (3, 9, 10), suggesting that these individuals might have an immune deficit. A minority of these children exhibit decreased immunoglobulin A (IgA) levels and poor antibody responses to polysaccharide antigens (9). However, these uncommon abnormalities cannot explain the recurrent infections seen in most children with MECP2 duplication (3). The IRAK1 gene encodes a serine-threonine kinase that lies adjacent to the MECP2 gene and is typically duplicated in MECP2 duplication syndrome. IRAK1 is an intermediate signaling molecule in the Toll-like receptor (TLR) signaling pathway and is important for activation and regulation of innate and adaptive immunity (1113). Aberrant expression of IRAK1 in MECP2 duplication syndrome is therefore a potential cause of immune dysfunction.

Similar to its role in neuronal cell function as a regulator of chromatin structure and gene expression (1), MeCP2 may regulate gene expression in immune cells where it is also expressed (14). There is a precedent for the involvement of proteins with epigenetic regulatory function in immunological disease. For example, loss-of-function mutations in the DNA methyltransferase 3B gene (DNMT3B) (15) result in centromeric chromosomal instabilities that underlie about 50% of cases of the immunodeficiency, centromeric instability, and facial anomalies (ICF1) syndrome (MIM: 242860) (16).

To determine whether MeCP2 overexpression influences immune function, we conducted detailed studies of human subjects with MECP2 duplication and studied mice in which a human MECP2 transgene is overexpressed from its own promoter (MeCP2Tg3 mice). Our studies confirm that MECP2 duplication is sufficient to confer immunological anomalies, which are manifested primarily by impaired secretion of the cytokine interferon-γ (IFN-γ) and reduced T helper cell type 1 (TH1) responses. Our findings establish a rational basis for identifying, treating, and preventing infectious complications potentially affecting children with MECP2 duplication.


Immunologic assessment of children with MECP2 duplication syndrome suggests immune deficiency

Previous studies of children with MECP2 duplication and triplication revealed a high incidence of recurrent infections, especially pneumonias (3, 8, 10). Infectious and inflammatory complications included life-threatening influenza B pneumonia with bacterial sepsis and oxygen-dependent chronic lung disease (Table 1) (8). To further address the apparent immunodeficiency in our own cohort of affected children with MECP2 duplication, we reviewed the medical records of 10 affected children who are followed clinically at the Blue Bird Circle Rett Center at Texas Children’s Hospital (TCH). Nine of our 10 patients with MECP2 duplication experienced recurrent respiratory tract infections, including severe lower respiratory tract infections such as pneumonia (8 of 10) requiring hospitalization (Table 1). These findings confirm a high prevalence of especially pulmonary complications in children with MeCP2 overexpression.

Table 1
Infectious disease history summary of children with MeCP2 overexpression.

In keeping with previous observations (9), serum Ig levels including IgA, IgG, IgM, and IgE were normal with the exception of low IgA levels in two children with MECP2 duplication (fig. S1 and table S1). Moreover, the production of specific IgG against diphtheria and tetanus toxoids and Haemophilus influenzae after boost vaccination was also abnormally attenuated in some, but not all, children (fig. S1 and table S1). In contrast, peripheral blood mononuclear cell (PBMC) responses to mitogenic stimulation were normal (fig. S4). Thus, patients from our local MECP2 duplication syndrome cohort manifested objective evidence of immune anomalies, including mucosal inflammatory complications of the respiratory tract and variable Ig assay abnormalities.

To extend these findings, we prospectively collected and studied immune cells from 27 children with MECP2 duplication syndrome having no signs or symptoms of acute disease. Total peripheral blood leukocyte counts of affected children were normal (Fig. 1A). However, when expressed as a percent of total leukocytes relative to established normal values, children with MECP2 duplication manifested significantly reduced mature neutrophils and, reciprocally, increased immature neutrophils, which indicates concurrent infection or inflammation (Fig. 1, B and C). Peripheral blood eosinophils, basophils, and monocytes were also increased in number (Fig. 1, D to F), suggesting prominent activation of the innate immune system, although these abnormalities were not seen in children of all age groups.

Fig. 1
Children with MECP2 duplication syndrome have reduced numbers of memory T and B cells and NK cells. (A to F) Peripheral blood from 27 children with MECP2 duplication syndrome was analyzed for total leukocytes (A) and the leukocyte subgroups (B) mature ...

More detailed immunophenotyping of lymphocytes from children with MECP2 duplication by flow cytometry revealed an increase in total CD4+ T cells (CD4+CD45RA+) in peripheral blood, whereas total CD8+ T cells were normal (Fig. 1, G to I). Furthermore, reduced memory CD4+ T cells (CD45+CD4+CD45RO+) were accompanied by reciprocally increased naïve CD4+ T cells, together with reduced memory B cells (CD19+CD27+) and natural killer (NK) cells (CD56+), especially in younger affected children (Fig. 1, J to M). Total B cells were also reduced in older children (ages 10 to 18 years). These data are also presented, where available, as absolute leukocyte counts (fig. S2). Thus, although often subtle and inconsistently observed across children of different ages, these findings provide objective evidence of immune irregularities in affected boys, including reduced memory T and B cells and NK cells. Moreover, the increased numbers of innate immune cells in peripheral blood suggested the possibility of active infectious or inflammatory disease.

MeCP2 overexpression does not alter development of mouse immune cell lineages

To further delineate the possibility of immune dysfunction occurring as a result of MECP2 duplication, we next turned to a mouse model in which human MECP2, and not other genes or transcriptional elements, is overexpressed as a transgene (MeCP2Tg3 mice) (7, 17). As assessed by flow cytometry, the T cell lineage markers CD4 and CD8 were distributed normally among CD3+ T cells from both spleen and thymus of MeCP2Tg3 mice (Fig. 2A), indicating overall normal T cell development. The total numbers of lymphocytes in major subsets, including CD4+, CD8+, B cells (CD19+B220+) NK cells (NK1.1+), and memory/activated mouse T cells (CD44hiCD62lo CD4+), were also normal in MeCP2Tg3 mice (Fig. 2, B and C). Thus, MECP2 overexpression per se does not influence development and homeostasis of major T cell subsets in mice.

Fig. 2
MeCP2 overexpression does not alter immune system development and homeostasis in mice. Splenocytes and thymocytes from wild-type (WT) and MeCP2 overexpression (MeCP2Tg3) mice were analyzed for the frequency of major lymphocyte subsets and memory T cells ...

MeCP2Tg3 mice are not able to control Leishmania major infection and have impaired TH1 responses

To determine whether MeCP2 overexpression causes functional immunological deficits, we examined in transgenic mice how MeCP2 overexpression influences both TH cell development and control of a variety of infections. Relative to otherwise genetically identical control mice, MeCP2Tg3 mice failed to control infection because of the intracellular protozoan parasite Leishmania major as assessed by progressive footpad swelling (Fig. 3A). Furthermore, IFN-γ–secreting lymph node cells from L. major–infected MeCP2Tg3 mice were significantly reduced (Fig. 3B). This finding was of particular interest because IFN-γ from TH1 cells is required for control of L. major infection (18), suggesting that MeCP2 overexpression in T cells conferred a defect in TH1 development. To test this possibility, we adoptively transferred syngeneic wild-type CD4+ T cells into MeCP2Tg3 mice and determined the susceptibility of these T cell chimeric mice to L. major infection. Indeed, immune reconstitution with wild-type TH cells enhanced the ability of MeCP2Tg3 mice to mount lymph node IFN-γ responses and fully restored control of L. major infection as assessed by footpad swelling (Fig. 3, A and B).

Fig. 3
Impaired TH1, but normal TH2, responses in MeCP2Tg3 mice. (A and B) Impaired control of L. major infection and reduced IFN-γ responses in MeCP2Tg3 mice. WT (n = 7) Fvb and syngeneic MECP2 transgenic mice (MeCP2Tg3, n = 6) were infected in footpads ...

We conducted additional studies to understand whether MeCP2 overexpression influenced other TH cell developmental programs, especially TH2 responses that underlie allergic inflammation. In contrast to L. major–infected mice, MeCP2Tg3 mice infected intranasally with the fungus Aspergillus niger developed airway hyperresponsiveness as assessed by acetylcholine challenge, a canonical marker of airway obstruction in asthma; lung IL-4 responses, an index of TH2 cell development and recruitment to lung; and allergic inflammation as assessed by airway eosinophil recruitment, which were either identical or enhanced relative to wild-type mice. Notably, however, IFN-γ responses were markedly diminished in MeCP2Tg3 mouse lungs after infection with A. niger (Fig. 3, C to E). MeCP2Tg3 mice further showed no impairment in controlling the resulting airway fungal infection as assessed by fungal cultures of lung homogenates and mounted normal lung IL-17 responses, indicative of normal TH17 cell development, against A. niger (fig. S3). MeCP2Tg3 TH cells were also capable of differentiating into TH17 cells as efficiently as T cells from wild-type mice (fig. S3).

Together, these findings establish that MeCP2 overexpression in mice confers a selective defect in IFN-γ, but not IL-4 or IL-17A, production in diverse in vivo contexts but fails to resolve whether this reflects a global impairment in IFN-γ secretion or a lineage-specific defect in TH1 responses. To address this, we compared the ability of CD8 and CD4 T cells from MECP2 transgenic mice to differentiate into IFN-γ–secreting CD8+ cytotoxic T cells (Tc1) and TH1 cells in vitro under lineage biasing conditions. Surprisingly, Tc1 differentiation was not affected by MeCP2 overexpression, but TH1 development was markedly impaired (Fig. 3, F and G).

We further characterized the ability of MeCP2Tg3 mice to develop appropriate antibody responses. In mice, TH cells function to assist B cell production of appropriate IgG antibodies, with TH2 cells contributing to IgG1 responses and TH1 cells, primarily through IFN-γ, contributing to IgG2a responses (19). Immunization of mice with ovalbumin (OVA) revealed differential impairment of IgG responses, with no significant difference between wild-type and MeCP2Tg3 mice seen regarding IgG1 production, but significantly reduced IgG2a secretion was observed (Fig. 3H). Thus, MeCP2 overexpression confers a selective defect in IFN-γ secretion from TH cells, leading to impaired IgG2a secretion in mice.

MECP2 duplication impairs human TH1 cell differentiation

We further assessed TH1 differentiation from naïve CD4 T cells from subjects with MECP2 duplication. Similar to MeCP2Tg3 T cells, CD4+ T cells from affected subjects produced markedly less intracellular IFN-γ when cultured in vitro under either TH0 or TH1 biasing conditions and overall about one-third the total number of TH1 cells as compared to normal subjects (Fig. 4, A and B). Notably, this was not due to impaired proliferation (Fig. 4, C and D, and fig. S4). Thus, similar to findings from MeCP2Tg3 mice, CD4+ T cells from children with MECP2 duplication syndrome exhibit defective TH1 responses.

Fig. 4
CD4+ T cells from PBMCs of children with MECP2 duplication syndrome exhibit impaired TH1 differentiation and dysregulated proliferation in vitro. (A) Representative flow cytometric analyses of intracytoplasmic IFN-γ production (y axis) and cell ...

TLR signaling is unaffected in mononuclear cells from children with MECP2 duplication syndrome

Although the IRAK1 gene is duplicated together with MECP2 in MECP2 duplication syndrome (5, 6), IRAK1 is not duplicated in MeCP2Tg3 mice (7), providing an opportunity to test hypotheses regarding the role of this immunoregulatory serine/threonine kinase in altering immune function in MECP2 duplication syndrome (20). We therefore determined the response of PBMCs from affected subjects to TLR ligand stimulation to uncover any potential perturbation in TLR signaling. We found no significant difference in inflammatory cytokine production [IL-1β, IL-6, and TNF-α (tumor necrosis factor–α)] from these cells after stimulation with diverse TLR ligands (Fig. 5, A to C). Thus, independent of the aberrant expression of IRAK1, these findings support a primary role for MeCP2 in mediating the immune irregularities seen in MECP2 duplication syndrome.

Fig. 5
TLR signaling is unaffected in children with MECP2 duplication syndrome. Production of the indicated cytokines by PBMCs from children with MECP2 duplication syndrome (MECP2 dupl) after stimulation with the indicated TLR ligands was determined by multiplex ...

MECP2 overexpression suppresses T-bet–dependent IFN-γ transcription and sequesters the IFN-γ locus

We conducted additional experiments to determine the potential mechanism by which overexpression of MeCP2 impairs TH1 responses. In addition to reduced IFN-γ protein production, both MECP2 transgenic mouse T cells and T cells from study participants with MECP2 duplication syndrome produced reduced levels of IFN-γ mRNA after stimulation under TH1 biasing conditions, suggesting that MeCP2 suppressed ifng transcription (Fig. 6, A and B).

Fig. 6
MeCP2 overexpression suppresses T-bet–dependent IFN-γ transcription. (A and B) IFN-γ mRNA level is regulated at the transcriptional level in TH1 cells from both MeCP2Tg3 mice and children with MECP2 duplication. (A) CD4+ splenocytes ...

MeCP2 binds to methylated CpG islands of DNA and either activates or suppresses gene expression, and previous work indirectly implicated MeCP2 as a regulatory factor in ifng transcription (21). We first considered the possibility that MeCP2 overexpression could suppress expression of transcription factors required for IFN-γ production such as T-bet, the principal factor controlling IFN-γ production and secretion from TH cells (22). However, intracellular staining of human T cells confirmed that T-bet expression is actually enhanced in the setting of MECP2 duplication (Fig. 6C).

We next considered the possibility that overexpressed MeCP2 could directly suppress IFN-γ transcription. When expressed together with T-bet in the human T cell line Jurkat, MeCP2 markedly inhibited endogenous IFN-γ transcription (Fig. 6D). Transfection of a MeCP2-specific small interfering RNA (siRNA) into naïve CD4+ T cells from children with MECP2 duplication syndrome both significantly reduced MECP2 transcripts and partially restored IFN-γ mRNA levels, suggesting that overexpression of MeCP2 is directly linked to the suppression of IFN-γ transcription (Fig. 6E).

The IFN-γ promoter in naïve T cells is unmethylated (23), suggesting that methyl-CpG binding fails to explain this result. However, MeCP2 can also bind to nonmethylated DNA (24, 25) and affect large-scale chromatin reorganization independent of DNA modification as a major mechanism for gene suppression (26). To further explore this possibility, we performed chromatin immunoprecipitation (ChIP) assays using mouse TH cells to determine the accessibility of the IFN-γ gene in the setting of MeCP2 overexpression. These studies demonstrated that, relative to wild-type cells, in the setting of MeCP2 overexpression, the IFN-γ locus is less likely to associate with acetylated histone protein 3 (Fig. 6, F and G). Thus, when overexpressed, MeCP2 renders the IFN-γ gene relatively inaccessible to transcriptional activation, most likely by sequestering the IFNG locus in association with histone proteins.


In addition to profound neurological disability, MECP2 duplication syndrome is characterized by recurrent pneumonias and other inflammatory complications. We have combined studies of children with MECP2 duplication and mice with a homologous alteration to determine whether overexpression of the MECP2 gene causes immune dysfunction. Our findings confirm that when overexpressed in human and mouse TH cells, MECP2 selectively impairs IFN-γ secretion and TH1 responses by acting as a transcriptional repressor and regulator of ifng locus accessibility. These findings indicate that children with duplication or triplication of the MECP2 gene have immune impairments related to their inability to mount robust TH1 responses, and suggest that the high frequency of pulmonary and other inflammatory complications affecting these children may be due to opportunistic pathogens.

A limitation of these studies is that although reduced TH1 responses were observed equally in humans and mice with MECP2 duplication, not all human immune abnormalities were reflected in the mouse. The markedly abnormal cell counts from peripheral blood of affected children that were not seen in the transgenic mice most likely represent differences in the environments encountered by humans and inbred research mice: Whereas humans constantly encounter pathogens from birth, specific pathogen–free (SPF) mice do not. We speculate that the relative lack of memory CD4+ T cells, balanced by reciprocal increases in naïve T cells, in children with MECP2 duplication is potentially explained by their impaired TH1 generation in response to diverse pathogens encountered in infancy and childhood. Chronic, unresolved infections due to lack of TH1 responses in these children could also explain the marked immaturity and increased abundance of neutrophils, eosinophils, and monocytes (Fig. 1). Relative lack of TH1 help could also explain the variable defects in antibody responses of some affected children (fig. S1). Thus, although confirmatory studies are needed, a single defect involving deficient IFN-γ responses involving only TH cells potentially explains the diverse immunologic anomalies demonstrated in children as well as the discrepancies in observations between humans and mice with MECP2 duplication.

Additionally, the mechanism by which MeCP2 controls gene expression in neurons and especially immune cells such as T cells remains incompletely understood. MeCP2 binds promiscuously and relatively homogeneously to chromosomal DNA, including methylated and nonmethylated regions, and may either transcriptionally suppress or enhance expression of neuronal genes (27). Little evidence exists to suggest that a major role of MeCP2 is to target individual genes to regulate their expression. Rather, MeCP2 appears to globally influence gene expression subtly and indirectly in a manner analogous to histone proteins by regulating chromosomal architecture (28).

In contrast, our findings suggest that, when overexpressed, MeCP2 interacts specifically with T-bet to inhibit ifng transcription. The Sin3A-HDAC (histone deacetylase) complex is displaced by T-bet at the ifng locus, which, although possibly only a correlative observation, may be important for the induction of ifng transcription and proper TH1 differentiation (29). Sin3A-HDAC is recruited by MeCP2 to target gene loci to suppress gene transcription, strongly supporting the importance of the Sin3A-HDAC/MeCP2 complex in the regulation of IFN-γ production (30). Although speculative, it is possible that increased binding of MeCP2 to T-bet in the setting of MECP2 duplication may be sufficient to preclude the full displacement of Sin3A-HDAC at the IFNG promoter, leading to DNA hypoacetylation and condensation on histone proteins.

Several human immunodeficiency syndromes are marked by deficiency in IFN-γ activity and involve genetic mutations in the IFN-γ receptor, signal transducer and activator of transcription 1 (STAT1), and the IL-12 receptor β1 (IL-12Rβ1) chain. Patients with these mutations exhibit profound immunodeficiency marked by susceptibility to lethal invasive infections due to intracellular pathogens such as bacteria and viruses (3134). Pneumonia, often due to mycobacteria, is a consistent clinical finding in these patients, but infections due to viruses and other bacteria have also been described (31, 32, 34). These findings in patients with unrelated genetic anomalies that underlie parallel immune irregularities further suggest that the pneumonias seen in children with MECP2 duplication may be infectious in nature and caused by immune dysfunction, specifically impaired IFN-γ, and not solely by neurological impairments.

Notably, however, IFN-γ secretion and TH1 responses are not entirely ablated in the setting of MeCP2 overexpression (Fig. 4), perhaps reflecting subtle differences in the intranuclear levels of MeCP2 in immune cells in the setting of gene duplication. Defective IFN-γ responses were further limited to TH cells, although we cannot exclude the possibility that MeCP2 duplication confers an IFN-γ defect in NK cells. Together, these issues may explain the variable immune phenotypes observed in our cohort with MECP2 duplication and the possibly attenuated infectious disease course of children with MECP2 duplication syndrome as compared to the more severe global IFN-γ deficiencies (such as IL-12Rβ1 deficiency) in which disseminated infections are often seen (35). IFN-γ further serves as a growth and differentiation factor for NK cells (36). This suggests that the mild deficiency in NK cells observed in our study subjects with MeCP2 overexpression could be due to the relative lack of the trophic effects of IFN-γ, although the reduction in NK cells could also be related to the depleting effects of recurrent infections.

In summary, we have shown that in addition to neurological phenotypes, duplication of the MECP2 gene causes immune dysfunction due in part to the suppression of IFN-γ production from TH cells. Affected children may be susceptible to infections caused by a wide variety of intracellular pathogens that are capable of causing pneumonia and other infections and possibly contributing to CNS disease. Identifying specific infectious agents that contribute to pneumonia and possibly neurological decline in children with MECP2 duplication will help to clarify the extent and severity of immune dysfunction.


Human subjects and sample collection

All experimental procedures were approved by the Institutional Review Board of Baylor College of Medicine and TCH. Participants received a diagnosis of MECP2 duplication syndrome according to standard molecular criteria. Blood samples were collected from 27 consecutive individuals with a diagnosis of MECP2 duplication syndrome confirmed by review of medical records and clinical genetic testing results and from 26 age-matched control subjects who assembled at Baylor College of Medicine for the 1st International MECP2 Duplication Syndrome Family Conference in May 2011. Unrelated controls were recruited through the TCH phlebotomy laboratory and were prospectively recruited at the time of a clinical blood draw. Subjects were excluded if they had a clinical diagnosis suggesting the possibility of immune deficiency (such as recurrent infections, organ transplant, primary immunodeficiency, and autoimmune disease), if they were taking immunomodulating therapies, or if they had signs/symptoms of active infection at the time of the blood draw.


Fvb/NJ mice were purchased from Jackson Laboratories and used as controls for mice with duplication of the MECP2 gene (FVB/N MeCPTg3) (7). MeCPTg3 mice contain a 99-kb human PAC (P1 artificial chromosome) clone that contains all exons of the MECP2 gene and no other transcriptional units or exons. All experiments included male mice between the ages of 4 and 6 weeks. Mice were bred under SPF conditions, and all animal protocols were approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine.

Antibodies and reagents

Except where otherwise indicated, all antibodies and cytokines were purchased from BD Biosciences. Anti–acetyl-histone H3 antibody was purchased from Millipore. Vector pcDNA3.1-MECP2A(E2)-CTAP containing a full-length human MECP2A complementary DNA (cDNA) with CTAP tag was generated by first subcloning human MECP2A(E2) cDNA from vector MECP2-pBi-EGFP (37) into pMK33-CTAP (GenBank accession no. AY727854) and then subcloning the MECP2A(E2)-CTAP fusion into pcDNA3.1 vector (Invitrogen). Vector expressing human TBX21 was purchased from GeneCopoeia.

Cells and cultures

PBMCs were isolated with standard Ficoll-Hypaque procedure as previously described (38). CD4+ T cells were further purified by positive selection (Miltenyi) and cultured in RPMI 1640 with l-glutamine, penicillin-streptomycin, and 10% fetal bovine serum. Cells were activated with plate-bound anti-CD3 and anti-CD28 in the presence of IL-2 (TH0 condition) or in the presence of recombinant human IL-12 (10 ng/ml) and antibodies to IL-4 (10 μg/ml) to induce TH1 differentiation. Naïve mouse CD4+ T cells were purified by positive immunomagnetic selection (Miltenyi) from splenocytes. Naïve CD4+ T cells were cultured in plates coated with anti-CD3 and anti-CD28 monoclonal antibodies (mAbs) in supplementary IL-2 (neutral conditions) or also with recombinant murine IL-12 and anti–IL-4 mAb (10 μg/ml) (TH1 conditions) or recombinant murine IL-6, IL-1β, and transforming growth factor–β (TH17 conditions) for 3 to 7 days.

Flow cytometry

Human and mouse cells were stained with the indicated antibodies, and flow cytometry data were collected with a BD LSRII (BD Biosciences) and analyzed by FlowJo software (Tree Star). For intracellular cytokine and protein detection, cells were restimulated with phorbol 12-myristate 13-acetate and ionomycin in the presence of monensin (BD Biosciences) for 5 hours at 37°C in 5% CO2. Cells were then fixed and stained with Cytofix/Cytoperm kit (BD Biosciences). Dilution of the fluorescent cytoplasmic stain CFSE (Invitrogen) was used to detect proliferating cells according to the manufacturer’s instructions.

TLR stimulation assay

Cytokine secretion in response to TLR ligand stimulation was assessed from peripheral blood by ARUP Laboratories.

Leishmania infection

L. major strain (MRHO/SU/59/P/LV39) was maintained and cultured as described (39, 40). Mice were infected with 2 × 106 stationary-phase L. major promastigotes in the hind footpads. MeCP2Tg3 mice were intraperitoneally transferred with 107 CD4+ T cells 24 hours before infection. Footpad thickness was monitored weekly over 80 days after infection with a micrometer. Cytokine-secreting popliteal lymph node cells were detected by ELISpot assay (41).

Analysis of allergic lung disease

Mice were intranasally challenged with 400 × 103 conidia of A. niger every other day for 2 weeks. Airway responsiveness to acetylcholine challenge, BAL fluid collection, and enumeration of total lung IL-4–and IFN-γ–secreting cells by ELISpot were performed as previously described (4244).

Allergen sensitization

Mice were sensitized with OVA precipitated in alum (OVA/alum) once a week for 3 weeks, and OVA-specific IgG isotype production was determined by ELISA as previously described (41, 42).

Cell transfection

Jurkat T cells were transfected with the Amaxa Jurkat Nucleofector Kit (Lonza) according to the manufacturer’s instructions. Cells were then incubated for 48 hours in 37°C with 5% CO2.

MECP2 siRNA knockdown

Silencer Select siRNA targeting MECP2 gene was purchased from Life Technologies predesigned siRNA sequences GCUUCCCGAUUAACUGAAAtt (sense) and UUUCAGUUAAUCGGGAAGCtt (antisense). Silencer Select Negative Control siRNA was used as negative control. CD4+ T cells from patients were nucleofected with either control or MECP2-specific siRNA according to the manufacturer’s protocol. Cells were used for functional studies 24 hours after nucleofection.

mRNA isolation and qPCR

Cell pellets were lysed with TRIzol (Invitrogen), and mRNA was extracted for qPCR according to the manufacturer’s directions. Probes for Ifng (Hs00989291_m1) and Mecp2 (Hs00172845_m1) were purchased from Applied Biosystems. Gene expression was normalized to 18S ribosomal RNA (Hs99999901_s1) expression.

ChIP assay

ChIP experiments were performed with Pierce Agarose ChIP Kit (Thermo Fisher Scientific) according to the manufacturer’s protocols. In brief, for each analysis, 2 × 106 differentiated TH1 cells were cross-linked with 1% formaldehyde at room temperature (RT) for 10 min, and then the reaction was stopped with 0.2 M glycine for 5 min at RT. Chromatin was digested with micrococcal nuclease (8 U/μl), and sheared chromatin was immunoprecipitated with anti–acetyl-histone H3 antibody or rabbit IgG together with agarose beads overnight at 4°C. DNA was thereafter purified from the mixture, and a 252–base pair region of the IFN-γ promoter was amplified (forward primer, 5′-CGTAATCCCGAGGAGCCTTC-3′; reverse primer, 5′-CTTTCAATGACTGTGCCGTGG-3′) by PCR.

Data and statistical analyses

Aggregate data are presented as means ± SEM. Prism software was used for statistical analyses. Except for airway physiology data, which were log-transformed to achieve a normal distribution suitable for analysis with the two-tailed Student’s t test, significant differences between paired samples were analyzed with the Mann-Whitney U test. Comparisons of immune phenotyping data in which subject data are compared to a clinically established normal range (95th percentile) were performed with the R program binominal distribution. A P value of less than 0.05 was considered significant for all analyses.

Supplementary Material

Supplementary Materials


We thank M. Boothby and T. Aune (Vanderbilt University) for the Ifng promoter-luciferase vector and the children and their families who made this study possible.

Funding: Funding support provided by NIH grants HL75243, AI057696, and AI070973 (to D.B.C.); NS062711 (to M.B.R.); and NS057819 and HD024064 (to H.Y.Z.).



Author contributions: T.Y., M.B.R., and D.B.C. designed and performed all experiments. W.L. supervised airway physiology experiments and cell cultures. L.R. performed PBMC isolation. J.K. supervised and assisted with Leishmania infection experiments. J.L.N., C.S.W., H.Y.Z., and F.K. provided technical interpretation of experiments and critical reagents, and assisted with manuscript writing. T.Y. wrote the first draft of the manuscript, performed all experiments, interpreted all results, and wrote the manuscript. D.B.C. and M.B.R. conceived the project and assisted with data interpretation.

Competing interests: The authors declare that they have no competing interests.


1. Guy J, Cheval H, Selfridge J, Bird A. The role of MeCP2 in the brain. Annu. Rev. Cell Dev. Biol. 2011;27:631–652. [PubMed]
2. Lubs H, Abidi F, Bier JA, Abuelo D, Ouzts L, Voeller K, Fennell E, Stevenson RE, Schwartz CE, Arena F. XLMR syndrome characterized by multiple respiratory infections, hypertelorism, severe CNS deterioration and early death localizes to distal Xq28. Am. J. Med. Genet. 1999;85:243–248. [PubMed]
3. Ramocki MB, Tavyev YJ, Peters SU. The MECP2 duplication syndrome. Am. J. Med. Genet. A. 2010;152A:1079–1088. [PMC free article] [PubMed]
4. Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, Hollanders K, Lugtenberg D, Bienvenu T, Jensen LR, Gecz J, Moraine C, Marynen P, Fryns JP, Froyen G. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am. J. Hum. Genet. 2005;77:442–453. [PubMed]
5. Carvalho CM, Zhang F, Liu P, Patel A, Sahoo T, Bacino CA, Shaw C, Peacock S, Pursley A, Tavyev YJ, Ramocki MB, Nawara M, Obersztyn E, Vianna-Morgante AM, Stankiewicz P, Zoghbi HY, Cheung SW, Lupski JR. Complex rearrangements in patients with duplications of MECP2 can occur by fork stalling and template switching. Hum. Mol. Genet. 2009;18:2188–2203. [PMC free article] [PubMed]
6. del Gaudio D, Fang P, Scaglia F, Ward PA, Craigen WJ, Glaze DG, Neul JL, Patel A, Lee JA, Irons M, Berry SA, Pursley AA, Grebe TA, Freedenberg D, Martin RA, Hsich GE, Khera JR, Friedman NR, Zoghbi HY, Eng CM, Lupski JR, Beaudet AL, Cheung SW, Roa BB. Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males. Genet. Med. 2006;8:784–792. [PubMed]
7. Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, Noebels JL, David Sweatt J, Zoghbi HY. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 2004;13:2679–2689. [PubMed]
8. Carvalho CM, Ramocki MB, Pehlivan D, Franco LM, Gonzaga-Jauregui C, Fang P, McCall A, Pivnick EK, Hines-Dowell S, Seaver LH, Friehling L, Lee S, Smith R, Del Gaudio D, Withers M, Liu P, Cheung SW, Belmont JW, Zoghbi HY, Hastings PJ, Lupski JR. Inverted genomic segments and complex triplication rearrangements are mediated by inverted repeats in the human genome. Nat. Genet. 2011;43:1074–1081. [PMC free article] [PubMed]
9. Friez MJ, Jones JR, Clarkson K, Lubs H, Abuelo D, Bier JA, Pai S, Simensen R, Williams C, Giampietro PF, Schwartz CE, Stevenson RE. Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28. Pediatrics. 2006;118:e1687–e1695. [PubMed]
10. Tang SS, Fernandez D, Lazarou LP, Singh R, Fallon P. MECP2 triplication in 3 brothers—A rarely described cause of familial neurological regression in boys. Eur. J. Paediatr. Neurol. 2012;16:209–212. [PubMed]
11. Gottipati S, Rao NL, Fung-Leung WP. IRAK1: A critical signaling mediator of innate immunity. Cell. Signal. 2008;20:269–276. [PubMed]
12. Tun-Kyi A, Finn G, Greenwood A, Nowak M, Lee TH, Asara JM, Tsokos GC, Fitzgerald K, Israel E, Li X, Exley M, Nicholson LK, Lu KP. Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon–mediated immunity. Nat. Immunol. 2011;12:733–741. [PMC free article] [PubMed]
13. Deng C, Radu C, Diab A, Tsen MF, Hussain R, Cowdery JS, Racke MK, Thomas JA. IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity. J. Immunol. 2003;170:2833–2842. [PubMed]
14. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum. Mol. Genet. 2002;11:115–124. [PubMed]
15. Dhasarathy A, Wade PA. The MBD protein family—Reading an epigenetic mark? Mutat. Res. 2008;647:39–43. [PMC free article] [PubMed]
16. de Greef JC, Wang J, Balog J, den Dunnen JT, Frants RR, Straasheijm KR, Aytekin C, van der Burg M, Duprez L, Ferster A, Gennery AR, Gimelli G, Reisli I, Schuetz C, Schulz A, Smeets DF, Sznajer Y, Wijmenga C, van Eggermond MC, van Ostaijen-Ten Dam MM, Lankester AC, van Tol MJ, van den Elsen PJ, Weemaes CM, van der Maarel SM. Mutations in ZBTB24 are associated with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2. Am. J. Hum. Genet. 2011;88:796–804. [PubMed]
17. Samaco RC, Mandel-Brehm C, McGraw CM, Shaw CA, McGill BE, Zoghbi HY. Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome. Nat. Genet. 2012;44:206–211. [PMC free article] [PubMed]
18. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 1995;13:151–177. [PubMed]
19. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR, Vitetta ES. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 1988;334:255–258. [PubMed]
20. Rao N, Nguyen S, Ngo K, Fung-Leung WP. A novel splice variant of interleukin-1 receptor (IL-1R)-associated kinase 1 plays a negative regulatory role in Toll/IL-1R-induced inflammatory signaling. Mol. Cell. Biol. 2005;25:6521–6532. [PMC free article] [PubMed]
21. Tong Y, Aune T, Boothby M. T-bet antagonizes mSin3a recruitment and transactivates a fully methylated IFN-γ promoter via a conserved T-box half-site. Proc. Natl. Acad. Sci. U.S.A. 2005;102:2034–2039. [PubMed]
22. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100:655–669. [PubMed]
23. Jones B, Chen J. Inhibition of IFN-γ transcription by site-specific methylation during T helper cell development. EMBO J. 2006;25:2443–2452. [PubMed]
24. Adams VH, McBryant SJ, Wade PA, Woodcock CL, Hansen JC. Intrinsic disorder and autonomous domain function in the multifunctional nuclear protein, MeCP2. J. Biol. Chem. 2007;282:15057–15064. [PubMed]
25. Meehan RR, Lewis JD, Bird AP. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 1992;20:5085–5092. [PMC free article] [PubMed]
26. Georgel PT, Horowitz-Scherer RA, Adkins N, Woodcock CL, Wade PA, Hansen JC. Chromatin compaction by human MeCP2. Assembly of novel secondary chromatin structures in the absence of DNA methylation. J. Biol. Chem. 2003;278:32181–32188. [PubMed]
27. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008;320:1224–1229. [PMC free article] [PubMed]
28. Cohen S, Gabel HW, Hemberg M, Hutchinson AN, Sadacca LA, Ebert DH, Harmin DA, Greenberg RS, Verdine VK, Zhou Z, Wetsel WC, West AE, Greenberg ME. Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron. 2011;72:72–85. [PMC free article] [PubMed]
29. Chang S, Collins PL, Aune TM. T-bet dependent removal of Sin3A-histone deacetylase complexes at the Ifng locus drives Th1 differentiation. J. Immunol. 2008;181:8372–8381. [PMC free article] [PubMed]
30. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998;393:386–389. [PubMed]
31. Sologuren I, Boisson-Dupuis S, Pestano J, Vincent QB, Fernández-Pérez L, Chapgier A, Cárdenes M, Feinberg J, García-Laorden MI, Picard C, Santiago E, Kong X, Jannière L, Colino E, Herrera-Ramos E, Francés A, Navarrete C, Blanche S, Faria E, Remiszewski P, Cordeiro A, Freeman A, Holland S, Abarca K, Valerón-Lemaur M, Gonçalo-Marques J, Silveira L, García-Castellano JM, Caminero J, Pérez-Arellano JL, Bustamante J, Abel L, Casanova JL, Rodriguez-Gallego C. Partial recessive IFN-γR1 deficiency: Genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum. Mol. Genet. 2011;20:1509–1523. [PMC free article] [PubMed]
32. Vairo D, Tassone L, Tabellini G, Tamassia N, Gasperini S, Bazzoni F, Plebani A, Porta F, Notarangelo LD, Parolini S, Giliani S, Badolato R. Severe impairment of IFN-γ and IFN-α responses in cells of a patient with a novel STAT1 splicing mutation. Blood. 2011;118:1806–1817. [PubMed]
33. Prando C, Boisson-Dupuis S, Grant AV, Kong XF, Bustamante J, Feinberg J, Chapgier A, Rose Y, Janniere L, Rizzardi E, Zhang Q, Shanahan CM, Viollet L, Lyonnet S, Abel L, Ruga EM, Casanova JL. Paternal uniparental isodisomy of chromosome 6 causing a complex syndrome including complete IFN-γ receptor 1 deficiency. Am. J. Med. Genet. A. 2010;152A:622–629. [PMC free article] [PubMed]
34. Averbuch D, Chapgier A, Boisson-Dupuis S, Casanova JL, Engelhard D. The clinical spectrum of patients with deficiency of signal transducer and activator of transcription-1. Pediatr. Infect. Dis. J. 2011;30:352–355. [PubMed]
35. de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, Al-Muhsen S, Jannière L, Rose Y, de Suremain M, Kong XF, Filipe-Santos O, Chapgier A, Picard C, Fischer A, Dogu F, Ikinciogullari A, Tanir G, Al-Hajjar S, Al-Jumaah S, Frayha HH, AlSum Z, Al-Ajaji S, Alangari A, Al-Ghonaium A, Adimi P, Mansouri D, Ben-Mustapha I, Yancoski J, Garty BZ, Rodriguez-Gallego C, Caragol I, Kutukculer N, Kumararatne DS, Patel S, Doffinger R, Exley A, Jeppsson O, Reichenbach J, Nadal D, Boyko Y, Pietrucha B, Anderson S, Levin M, Schandené L, Schepers K, Efira A, Mascart F, Matsuoka M, Sakai T, Siegrist CA, Frecerova K, Bluetters-Sawatzki R, Bernhöft J, Freihorst J, Baumann U, Richter D, Haerynck F, De Baets F, Novelli V, Lammas D, Vermylen C, Tuerlinckx D, Nieuwhof C, Pac M, Haas WH, Muller-Fleckenstein I, Fleckenstein B, Levy J, Raj R, Cohen AC, Lewis DB, Holland SM, Yang KD, Wang X, Wang X, Jiang L, Yang X, Zhu C, Xie Y, Lee PP, Chan KW, Chen TX, Castro G, Natera I, Codoceo A, King A, Bezrodnik L, Di Giovani D, Gaillard MI, de Moraes-Vasconcelos D, Grumach AS, da Silva Duarte AJ, Aldana R, Espinosa-Rosales FJ, Bejaoui M, Bousfiha AA, Baghdadi JE, Ozbek N, Aksu G, Keser M, Somer A, Hatipoglu N, Aydogmus C, Asilsoy S, Camcioglu Y, Gülle S, Ozgur TT, Ozen M, Oleastro M, Bernasconi A, Mamishi S, Parvaneh N, Rosenzweig S, Barbouche R, Pedraza S, Lau YL, Ehlayel MS, Fieschi C, Abel L, Sanal O, Casanova JL. Revisiting human IL-12Rβ1 deficiency: A survey of 141 patients from 30 countries. Medicine. 2010;89:381–402. [PMC free article] [PubMed]
36. Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, Sun JC, Lindsten T, Reiner SL. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity. 2012;36:55–67. [PMC free article] [PubMed]
37. Alvarez-Saavedra M, Sáez MA, Kang D, Zoghbi HY, Young JI. Cell-specific expression of wild-type MeCP2 in mouse models of Rett syndrome yields insight about pathogenesis. Hum. Mol. Genet. 2007;16:2315–2325. [PubMed]
38. Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J, Hacken J, Espada R, Bag R, Lewis DE, Kheradmand F. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med. 2004;1:e8. [PMC free article] [PubMed]
39. Corry DB, Reiner SL, Linsley PS, Locksley RM. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J. Immunol. 1994;153:4142–4148. [PubMed]
40. Soong L, Xu JC, Grewal IS, Kima P, Sun J, Longley BJ, Jr., Ruddle NH, McMahon-Pratt D, Flavell RA. Disruption of CD40–CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity. 1996;4:263–273. [PubMed]
41. Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener-Kronish JP, Locksley RM. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J. Exp. Med. 1996;183:109–117. [PMC free article] [PubMed]
42. Kheradmand F, Kiss A, Xu J, Lee SH, Kolattukudy PE, Corry DB. A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J. Immunol. 2002;169:5904–5911. [PubMed]
43. Corry DB, Grünig G, Hadeiba H, Kurup VP, Warnock ML, Sheppard D, Rennick DM, Locksley RM. Requirements for allergen-induced airway hyperreactivity in T and B cell-deficient mice. Mol. Med. 1998;4:344–355. [PMC free article] [PubMed]
44. Xu J, Park PW, Kheradmand F, Corry DB. Endogenous attenuation of allergic lung inflammation by syndecan-1. J. Immunol. 2005;174:5758–5765. [PubMed]